/news/b/pressreleases/archive/2021/01/14/pharmasyntez-to-help-skolkovo-resident-promote-drug-against-leukemia.aspxFusion Pharma, a resident of the Skolkovo Foundation's Biomedical Technologies Cluster, signed a license agreement with Pharmasyntez to commercialize an innovative antileukemic drug. The licencing deal implies an upfront payment, milestones and royalties7.x Production